AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
Phase 1
Recruiting
- Conditions
- Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT06899061
- Locations
- 🇷🇴
Research Site, Cluj Napoca, Romania
An Ophthalmic Safety Study in Patients With Breast Cancer
Recruiting
- Conditions
- Ophthalmic Safety in Patients With Breast Cancer
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT06767462
- Locations
- 🇪🇸
Research Site, Salamanca, Spain
Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 540
- Registration Number
- NCT06890351
- Locations
- 🇹🇭
Research Site, Nakhon Sri Thammarat, Thailand
NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Not yet recruiting
- Conditions
- Endometrial Cancer
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06890273
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Hyperkalemia Quality Improvement Program (HK-QIP) Study
Not Applicable
Not yet recruiting
- Conditions
- Hyperkalemia Patient With Non-Dialysis Chronic Kidney Disease
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06884267
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD
Phase 3
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 990
- Registration Number
- NCT06883305
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Drug: AZD2287Drug: AZD2284Drug: AZD2275
- First Posted Date
- 2025-03-17
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 134
- Registration Number
- NCT06879041
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
Phase 3
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Other: Placebo
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 990
- Registration Number
- NCT06878261
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 830
- Registration Number
- NCT06868277
- Locations
- 🇬🇧
Research Site, Blackpool, United Kingdom
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab
Not yet recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06862206
- Locations
- 🇨🇳
Beijing Haidian Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chaoyang Hospital, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath